- Despite recent spinoff from Johnson & Johnson, Kenvue overcomes expectations with robust Q2 results.
- Shares show signs of turbulence, but Kenvue stands strong with a promising sales outlook for 2023.
- Kenvue battles with legacy lawsuits, assures only a small number are material.
Kenvue, a recent spinoff from Johnson & Johnson, delivered a promising financial report this Thursday, surpassing predicted Q2 earnings and revenue, thus starting its independent journey on a high note.
Two months into its departure from Johnson & Johnson, Kenvue, which hosts an assortment of famous brands like Band-Aid, Tylenol, Neutrogena, and more, provided a buoyant sales forecast for 2023. However, the direction of Kenvue's operations remains largely influenced by J&J, owning a dominant 90% stake in the company. Yet, J&J plans to loosen its grip and trim its ownership later this year.
As part of its quarterly earnings release, J&J also announced the performance of Kenvue. Against the expectations of Refinitiv's analysts' survey, Kenvue posted an adjusted earning per share of 32 cents and a revenue of $4.01 billion, outperforming the predicted 30 cents and $3.96 billion respectively.
While Kenvue's initial public debut was well-received, its stock value has encountered turbulence due to concerns over future growth potential amidst consumer spending cutbacks. Despite this, Kenvue maintains a strong market value of approximately $47.9 billion, even after a 7% drop in stock value since its public launch.
Already profitable unlike many recent IPOs, Kenvue demonstrated Q2 sales of $4.01 billion, a 5.4% increase compared to last year. The company also reported a net income of $430 million. Kenvue predicts a sales growth between 4.5% to 5.5% for 2023 and full-year adjusted earnings per share ranging between $1.26 to $1.31. However, Kenvue's past continues to haunt, with thousands of lawsuits relating to talc baby powder, now under Kenvue's banner, alleging cancer causation. Yet, the company assures that only a negligible number of these are material at this stage.
WOM Money Picks
Be a part of the winning team | 81% Success Rate.